These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 33176813)

  • 1. Revisiting the association between skin toxicity and better response in advanced cancer patients treated with immune checkpoint inhibitors.
    Gulati N; Donnelly D; Qian Y; Moran U; Johannet P; Zhong J; Osman I
    J Transl Med; 2020 Nov; 18(1):430. PubMed ID: 33176813
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of an immunosuppressive therapy on the efficacy of immune checkpoint inhibition in metastatic melanoma - An analysis of the prospective skin cancer registry ADOREG.
    Kochanek C; Gilde C; Zimmer L; Ugurel S; Meier F; Utikal J; Pföhler C; Herbst R; Haferkamp S; Welzel J; Dücker P; Leiter U; Weichenthal M; von Wasielewski I; Angela Y; Gutzmer R
    Eur J Cancer; 2024 Feb; 198():113508. PubMed ID: 38183763
    [TBL] [Abstract][Full Text] [Related]  

  • 3. C-reactive protein flare predicts response to checkpoint inhibitor treatment in melanoma.
    Kött J; Zimmermann N; Zell T; Heidrich I; Geidel G; Rünger A; Smit DJ; Merkle M; Parnian N; Hansen I; Hoehne I; Abeck F; Torster L; Weichenthal M; Pantel K; Schneider SW; Gebhardt C
    J Eur Acad Dermatol Venereol; 2024 Aug; 38(8):1575-1587. PubMed ID: 38466133
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Influence of melanoma type on incidence and downstream implications of cutaneous immune-related adverse events in the setting of immune checkpoint inhibitor therapy.
    Nguyen N; Wan G; Ugwu-Dike P; Alexander NA; Raval N; Zhang S; Jairath R; Phillipps J; Leung B; Roster K; Seo J; Lu C; Tang K; Choi MS; DeSimone MS; Theodosakis N; Amadife M; Cox N; Le TK; Liu F; Chen W; Bai X; Boland G; Liu D; Hurlbert MS; LeBoeuf N; Reynolds KL; Yu KH; Tsao H; Asgari M; Gusev A; Kwatra SG; Semenov YR
    J Am Acad Dermatol; 2023 Jun; 88(6):1308-1316. PubMed ID: 36828138
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Total serum N-glycans associate with response to immune checkpoint inhibition therapy and survival in patients with advanced melanoma.
    Visconti A; Rossi N; Deriš H; Lee KA; Hanić M; Trbojević-Akmačić I; Thomas AM; Bolte LA; Björk JR; Hooiveld-Noeken JS; Board R; Harland M; Newton-Bishop J; Harries M; Sacco JJ; Lorigan P; Shaw HM; de Vries EGE; Fehrmann RSN; Weersma RK; Spector TD; Nathan P; Hospers GAP; Sasieni P; Bataille V; Lauc G; Falchi M
    BMC Cancer; 2023 Feb; 23(1):166. PubMed ID: 36805683
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Potential roles of sex-linked differences in obesity and cancer immunotherapy: revisiting the obesity paradox.
    Vick LV; Rosario S; Riess JW; Canter RJ; Mukherjee S; Monjazeb AM; Murphy WJ
    NPJ Metab Health Dis; 2024; 2(1):5. PubMed ID: 38800540
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association Between Systemic Corticosteroid Treatment for Cutaneous Immune-Related Adverse Events and Survival Outcomes in Patients With Advanced Cancer.
    Thompson LL; Yoon J; Krasnow NA; Chang MS; Li EB; McMahon DE; Chen ST
    JAMA Dermatol; 2021 Apr; 157(5):599-602. PubMed ID: 33851976
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Using Machine Learning Algorithms to Predict Immunotherapy Response in Patients with Advanced Melanoma.
    Johannet P; Coudray N; Donnelly DM; Jour G; Illa-Bochaca I; Xia Y; Johnson DB; Wheless L; Patrinely JR; Nomikou S; Rimm DL; Pavlick AC; Weber JS; Zhong J; Tsirigos A; Osman I
    Clin Cancer Res; 2021 Jan; 27(1):131-140. PubMed ID: 33208341
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical features of immune-mediated hepatotoxicity induced by immune checkpoint inhibitors in patients with cancers.
    Yamamoto A; Yano Y; Ueda Y; Yasutomi E; Hatazawa Y; Hayashi H; Yoshida R; Asaji N; Shiomi Y; Tobimatsu K; Sakai A; Kodama Y
    J Cancer Res Clin Oncol; 2021 Jun; 147(6):1747-1756. PubMed ID: 33222015
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Baseline prognostic nutritional index and changes in pretreatment body mass index associate with immunotherapy response in patients with advanced cancer.
    Johannet P; Sawyers A; Qian Y; Kozloff S; Gulati N; Donnelly D; Zhong J; Osman I
    J Immunother Cancer; 2020 Nov; 8(2):. PubMed ID: 33219093
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative Risks of High-Grade Adverse Events Among FDA-Approved Systemic Therapies in Advanced Melanoma: Systematic Review and Network Meta-Analysis.
    Huang YF; Xie WJ; Fan HY; Du J
    Front Oncol; 2020; 10():571135. PubMed ID: 33178599
    [No Abstract]   [Full Text] [Related]  

  • 12. Immune checkpoint inhibitor therapy may increase the incidence of treatment-related necrosis after stereotactic radiosurgery for brain metastases: a systematic review and meta-analysis.
    Kim PH; Suh CH; Kim HS; Kim KW; Kim DY; Aizer AA; Rahman R; Guenette JP; Huang RY
    Eur Radiol; 2021 Jun; 31(6):4114-4129. PubMed ID: 33241519
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A genomic signature for accurate classification and prediction of clinical outcomes in cancer patients treated with immune checkpoint blockade immunotherapy.
    Lu M; Wu KH; Trudeau S; Jiang M; Zhao J; Fan E
    Sci Rep; 2020 Nov; 10(1):20575. PubMed ID: 33239757
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinicopathological characteristics and management of colitis with anti-PD1 immunotherapy alone or in combination with ipilimumab.
    Nahar KJ; Rawson RV; Ahmed T; Tattersall S; Sandanayake N; Kiely CJ; Lo S; Carlino M; Palendira U; Scolyer RA; Long GV; Menzies AM
    J Immunother Cancer; 2020 Nov; 8(2):. PubMed ID: 33234603
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of concomitant medications with immune-modulatory properties on the outcomes of patients with advanced cancer treated with immune checkpoint inhibitors: development and validation of a novel prognostic index.
    Buti S; Bersanelli M; Perrone F; Tiseo M; Tucci M; Adamo V; Stucci LS; Russo A; Tanda ET; Spagnolo F; Rastelli F; Pergolesi F; Santini D; Russano M; Anesi C; Giusti R; Filetti M; Marchetti P; Botticelli A; Gelibter A; Occhipinti MA; Ferrari M; Vitale MG; Nicolardi L; Chiari R; Rijavec E; Nigro O; Tuzi A; De Tursi M; Di Marino P; Conforti F; Queirolo P; Bracarda S; Macrini S; Gori S; Zoratto F; Veltri E; Di Cocco B; Mallardo D; Vitale MG; Santoni M; Patruno L; Porzio G; Ficorella C; Pinato DJ; Ascierto PA; Cortellini A
    Eur J Cancer; 2021 Jan; 142():18-28. PubMed ID: 33212418
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lower risk of severe checkpoint inhibitor toxicity in more advanced disease.
    Verheijden RJ; May AM; Blank CU; van der Veldt AAM; Boers-Sonderen MJ; Aarts MJB; van den Berkmortel FWPJ; van den Eertwegh AJM; de Groot JWB; van der Hoeven JJM; Hospers GAP; Piersma D; van Rijn RS; Ten Tije AJ; Vreugdenhil G; van Zeijl MCT; Wouters MWJM; Haanen JBAG; Kapiteijn E; Suijkerbuijk KPM
    ESMO Open; 2020 Nov; 5(6):e000945. PubMed ID: 33199288
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neurologic Complications of Immune Checkpoint Inhibitors in Thoracic Malignancies.
    Sechi E; Zekeridou A
    J Thorac Oncol; 2021 Mar; 16(3):381-394. PubMed ID: 33188910
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The association between proton pump inhibitors use and clinical outcome of patients receiving immune checkpoint inhibitors therapy.
    Li M; Zeng C; Yao J; Ge Y; An G
    Int Immunopharmacol; 2020 Nov; 88():106972. PubMed ID: 33182025
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association of Preexisting Interstitial Lung Abnormalities With Immune Checkpoint Inhibitor-Induced Interstitial Lung Disease Among Patients With Nonlung Cancers.
    Shimoji K; Masuda T; Yamaguchi K; Sakamoto S; Horimasu Y; Nakashima T; Miyamoto S; Iwamoto H; Fujitaka K; Hamada H; Takeno S; Hide M; Teishima J; Ohdan H; Hattori N
    JAMA Netw Open; 2020 Nov; 3(11):e2022906. PubMed ID: 33180128
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inflammatory Myositis in Cancer Patients Receiving Immune Checkpoint Inhibitors.
    Aldrich J; Pundole X; Tummala S; Palaskas N; Andersen CR; Shoukier M; Abdel-Wahab N; Deswal A; Suarez-Almazor ME
    Arthritis Rheumatol; 2021 May; 73(5):866-874. PubMed ID: 33258544
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.